A Study Correlation between Levels IL-15, IL-23 and TNF-α in a Sample of Iraqi Psoriasis Patients
Main Article Content
Abstract
Abstract
Psoriasis is defined as a series of events that begins in its initial stage with dermatitis and then progresses to more widespread inflammation and increased oxidative stress. The aim of this study was to determine whether psoriasis and the levels of IL-15, IL-23, and TNF-α are related, the ELISA technique was used to detect the levels of inflammation in psoriasis patients and to compare them with healthy individuals. This study included 150 samples, including 90 patients with psoriasis and 60 healthy individuals, and the study was conducted from November 2021 to April 2022. The current study revealed that there was a significant difference in the level of TNF-α in the group of psoriasis patients compared to its level in healthy individuals. Also, there was a significant increase in the level of IL-23 in psoriasis patients compared to its level in the healthy individuals, while there was no significant difference in the level of IL15 between the two groups. However, the statistical study showed a positive and highly significant correlation between IL-15 and IL-23 levels in psoriasis patients, as well as the same relationship between IL-15 and TNF-α levels, in addition to a significant correlation between IL-23 and TNF-α levels in the group of patients. This shows that there is a clear association between these interleukins and psoriasis and its association with the inflammatory status of psoriasis patients, although there was no increase in the level of interleukin-15, the association of interleukin-15 with other inflammatory indicators proves its involvement in psoriasis and an indirect effect on the inflammatory state of psoriasis.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
licenseTermsHow to Cite
Publication Dates
References
Naldi, L. Epidemiology of psoriasis: current drug targets. Inflamm. Allergy, 2004; 3, 2, 121–128.
Numerof, R.P.; Asadullah, K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. J. Bio. Drugs, 2006; 20, 2,93-103.
Guðjónsson, J. E.; Valdimarsson, H.; Kárason, A.; Antonsdóttir, A. A.; Rúnarsdóttir, E. H.;Gulcher, J.R.; Stefánsson, K HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J. Investig. Dermatol. 2002, 118, 2, 362-365 .
World Heath Organization, Global Report in Psoriasis, 2016.
Kuba, R.H.; Al-Qadhi, B.N.; Fadheel, B.M.; Effect of the Biological Drug Etanercept on Tumor necrosis factor-α Levels in Psoriatic Patients. Iraqi J. Sci., 2018, 59, 2, 998–1005.
Guenther, L.; Gulliver, W. Psoriasis comorbidities. J. Cutan. Med. Surg. 2009; 13, 5,77-87.
Iqbal, M.N. Levels of interleukins 6 and 8 in Psoriatic patients serum. Ibn AL-Haitham J. Pure Appl. Sci., 2017, 23, 3, 15-24.
Abdul-Hussein, S.S.; Ali, E.N.; Alkhalidi, N.M.F.; Zaki, N.H.; Ad’hiah, A.H. Roles of IL-17A and IL-23 in the Pathogenesis of Ulcerative Colitis and Crohn’s Disease. Iraqi J. Sci., 2021; 62, 8, 2526–2535.
Lande, R.; Gregorio, J.; Facchinetti, V.; Chatterjee, B.; Wang, Y.H.; Homey, B.; Gilliet, M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. J. Nat., 2007; 449, 7162, 564-569.
Kauffman, C.L.; Aria, N., Toichi, E.; McCormick, T.S.; Cooper, K.D.; Gottlieb, A.B.; Mascelli, M.A.; A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Investig. Dermatol., 2004; 123, 6, 1037-1044.
Pietrzak, A.T.; Zalewska, A.; Chodorowska, G.; Krasowska, D.; Michalak-Stoma, A.; Nockowski, P.; Roliński, J.M. Cytokines and anticytokines in psoriasis. J. Clin. Chimica Acta, 2008; 394, 1-2, 7-21.
Budagian, V.; Bulanova, E.; Paus, R.; Bulfone-Paus, S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. J. Cytokine Growth Factor Rev., 2006; 17, 4, 259-280.
Dunphy, S.E.; Sweeney, C.M.; Kelly, G.; Tobin, A.M.; Kirby, B.; Gardiner, C.M. Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. J. Clin. Immunol., 2015; 177, 43-49.
Majeed, I.A.; Al-Shawi, N.N. Effects of Omega-3 Co-Administered with Therapeutic Dose of lornoxicam on Male Rats' Liver. Iraqi j. Pharmac. Sci., 2019; 28, 2, 159-164.
Arican, O.; Aral. M.; Sasmaz, S.; Ciragil P.; Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. J. Med. Inflamm., 2005; 5, 273-279.
Liu. T.; Li, S.; Ying, S. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. J. Front Immunol., 2020; 11, 59475.
Kuchař, M.; Vaňková, L.; Petroková, H.; Cerný, J.; Osička, R.; Pelák, O.; Sípová, H.; Schneider, B.; Homola, J.; Sebo, P.; Kalina, T.; Malý, P. Human interleukin‐23 receptor antagonists derived from an albumin‐binding domain scaffold inhibit IL‐23‐dependent ex vivo expansion of IL‐17‐producing T‐cells. J. Proteins Struct. Func. Bioinform., 2014; 82, 6, 975-989.
Myers, B.; Thibodeaux, Q.; Reddy, V. Biologic treatment of 4 HIV-positive patients: a case series and literature review. J. Psoriasis Psoriatic Arthritis, 2021; 6, 1, 19–26.
Abanmi, A.; Al Harthi, F.; Al-Agla. R. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int. J. Dermatol., 2005; 44, 1, 82-83.
Daniel. W.W.; Cross, C.L. Biostatistics, A Foundation for analysis in the health sciences. Journal of John Wiely and Sons 2013; 958.
Yost, J.; Gudjonsson, J.E. The role of TNF inhibitors in psoriasis therapy. New implications for associated comorbidities 2009; F1000 medicine reports 1.
Mizutani, H.; Ohmoto, Y.; Mizutani, T.; Murata, M.; Shimizu, M. Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J. Dermatol. Sci. 1997; 14, 2,145-153.
Uyemura, K.; Yamamura, M.; Fivenson, D.F.; Modlin, R.L.; Nickoloff, B.J; The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Investig. Dermatol., 1993; 101, 5,701-705.
De Rie, M.A.; Goedkoop, A.Y.; Bos, J.D. Overview of psoriasis. J. Dermatol. Therapy, 2004; 17, 5, 341-349.
Hong, J.J.; Hadeler, E.K.; Mosca, M.L.; Brownstone, N.D.; Bhutani, T. Liao, W.J. TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 Inhibitors. J. Psoriasis Psoriatic Arthritis, 2022; 7, 2, 79-92.
Domm. S.; Cinatl. J.; Mrowietz. U.; The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br. J. Dermatol., 2008; 159, 6, 1217–1228.
Myers, B.; Thibodeaux, Q.; Reddy. V. Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. J. Psoriasis Psoriatic Arthritis, 2021; 6, 1, 19–26.
Arican, O.; Aral, M.; Sasmaz, S.; Ciragil, P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. J. Mediators Inflamm., 2005; 2005, 5, 273–279.
Abanmi, A.; Al-Harthi, F.; Al-Agla, R. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int. J. Dermatol., 2005; 44, 1, 82–83.
Roussaki-Schulze. AV.; Kouskoukis. C.; Petinaki. E. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int. J. Clin. Pharmacol. Res., 2005; 25, 4, 169–73.
Fotiadou, C.; Lazaridou, E.; Sotiriou, E.; Ioannides, D. Targeting IL-23 in psoriasis: current perspectives. J. Psoriasis (Auckl), 2018; 8, 1, 1-5.
Dattola, A.; Silvestri, M.; Tamburi, F.; Amoruso, G. F.; Bennardo, L.; Nisticò. S.P. Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising. J. Dermatologic Therapy 2020; 33, 6, 14504
Wolk, K.; Witte, E.; Wallace, E.; Döcke, W.D.; Kunz, S.; Asadullah, K.; Volk, H.D.; Sterry, W.; Sabat, R. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Europ. J. Immunol., 2006; 36, 5, 1309-1323.
Takahashi, H.; Tsuji, H.; Hashimoto, Y.; Ishida-Yamamoto, A.; Iizuka, H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin. Exper. Dermatol, Exper. Dermatol., 2010; 35, 6, 645-649.
Vähävihu, K.; Ala-Houhala, M.; Peric, M.; Karisola, P.; Kautiainen, H.; Hasan, T.; Snellman, E.; Alenius, H.; Schauber, J.; Reunala, T. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br. J. Dermatol., 2010; 163, 2, 321-328.
Coimbra, S.; Oliveira, H.; Reis, F.; Belo, L.; Rocha, S.; Quintanilha, A.; Santos‐Silva. A. Interleukin (IL)‐22, IL‐17, IL‐23, IL‐8, vascular endothelial growth factor and tumour necrosis factor‐α levels in patients with psoriasis before, during and after psoralen–ultraviolet A and narrowband ultraviolet B therapy. Br. J. Dermatology 2010,163, 6, 1282-1290.
Girolomoni, G.; Strohal, R.; Puig, L.; Bachelez, H.; Barker, J.; Boehncke, W.H.; Prinz J. C. The role of IL‐23 and the IL‐23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J. Europ. Acad. Dermatol. Venereol., 2017; 31, 10, 1616-1626.
Curtis. M.M.; Way. S.S.; Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. J. Immunol. 2009; 126, 177-185.
Langrish, C.L.; Chen, Y.; Blumenschein, W.M.; Mattson, J.; Basham, B.; Sedgwick, J.D.; McClanahan, T.; Kastelein, R.A.; Cua, D. J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exper. Med., 2005; 201, 2, 233-240.
Dapavo, P.; Siliquini, N.; Mastorino, L.; Avallone, G.; Merli, M.; Agostini, A.; Ribero S; Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J. Dermatol. Treat. 2022; 33, 4, 2352-2357.
Dunphy, S.E.; Sweeney, C.M.; Kelly, G.; Tobin, A.M.; Kirby, B.; Gardiner, C.M. Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. J. Clin. Immunol., 2017; 177, 43-49.
Tassiulas, I.; Duncan, S.R.; Centola, M.; Theofilopoulos, A.N.; Boumpas, D.T. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. J. Human Immunol., 1999; 60, 6, 479-491.
Danning, C.L.; Illei, G.G.; Hitchon, C.; Greer, M.R.; Boumpas, D. T.; McInnes, I.B; Macrophage‐derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheumat. Official J. Am. Coll. Rheumatol., 2000, 43, 6, 1244-1256.
Dunphy, S.E.; Sweeney, C.M.; Kelly, G.; Tobin, A.M.; Kirby, B.; Gardiner C.M. Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. J. Clin. Immunol., 2017; 177, 43-49.
Kalinina, O.; Golovkin, A.; Zaikova, E.; Aquino, A.; Bezrukikh, V.; Melnik, O.; Shlyakhto, E. Cytokine Storm Signature in Patients with Moderate and Severe COVID-19. Int. J. Mol. Sci., 2022; 23, 16, 8879.
McInnes. I.B.; Liew. F.Y. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. J. Immunol. Today, 1998; 19, 2, 75-79.
de Jesús‐Gil, C.; Ruiz‐Romeu, E.; Ferran, M.; Sagristà, M.; Chiriac, A.; García, P.; Santamaria‐Babí, L.F. IL‐15 and IL‐23 synergize to trigger Th17 response by CLA+ T cells in psoriasis. Exper. Dermatol., 2020; 29, 7, 630-638.
Yoshihara, K.; Yamada, H.; Hori, A.; Yajima, T.; Kubo, C.; Yoshikai, Y. IL‐15 exacerbates collagen‐induced arthritis with an enhanced CD4+ T cell response to produce IL‐17. Europ. J. Immunol., 2007; 37, 10, 2744-2752.
de Jesús‐Gil, C.; Ruiz‐Romeu, E.; Ferran, M.; Sagristà, M.; Chiriac, A.; García, P,; Santamaria‐Babí, L.F. IL‐15 and IL‐23 synergize to trigger Th17 response by CLA+ T cells in psoriasis. J. Exper. Dermatol., 2020; 29, 7, 630-638.
Celis, R.; Planell, N.; Fernández-Sueiro, J.L.; Sanmartí, R.; Ramírez, J.; González-Álvaro, I.; Cañete, J.D; Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. J. Arthritis Res. Therapy, 2012; 14, 2, 1-9.
Waldmann, T.A. Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res. Ther, 2004; 6, 4,174–177.
Fraga, N.A.D.A.; Oliveira, M.D.F.P.D.; Follador, I.; Rocha, B.D.O.; Rêgo, V.R. Psoriasis and uveitis: a literature review. J. Anais brasileiros de dermatologia, 2012; 87, 877-883.